Viewing Study NCT06654050


Ignite Creation Date: 2025-12-24 @ 5:13 PM
Ignite Modification Date: 2025-12-24 @ 5:13 PM
Study NCT ID: NCT06654050
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2024-10-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module